Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CHKA | P35790 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28654383 | 1.00 | MMP2 (0.52) | MMP2MMP9MMP8MMP13KMT2A | |
| SCHEMBL4260907 | 0.88 | MAPT (0.53) | MMP2MMP9MMP8MMP13KMT2A | |
| SCHEMBL14670971 | 0.81 | KMT2A (0.72) | MMP2MMP9MMP8MMP13KMT2A | |
| SCHEMBL28664345 | 0.80 | SMO (0.55) | KMT2AMEN1SMONPC1ALDH1A1 | |
| SCHEMBL4258701 | 0.80 | KMT2A (0.63) | MMP2MMP9MMP8MMP13KMT2A | |
| SCHEMBL4409064 | 0.79 | SMO (0.54) | KMT2AMAPTMEN1SMOSMN1; SMN2 | |
| SCHEMBL28673270 | 0.79 | SMO (0.54) | MAPTSMORAB9ANPC1ALDH1A1 | |
| SCHEMBL28669024 | 0.79 | SMO (0.54) | MAPTSMORAB9ANPC1ALDH1A1 | |
| SCHEMBL28676292 | 0.76 | ALDH1A1 (0.55) | KMT2AMAPTMEN1L3MBTL1SMO | |
| SCHEMBL28664350 | 0.76 | SMO (0.51) | SMOALDH1A1CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404722-B2 | Oxazole compounds compositions and methods of use | AMGEN INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | disclosed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151495-A2 | OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | OXA1L, CYP11B2, CYP3A7 | MMP2 2966/4885MMP9 1899/4885MMP8 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.